Adjuvant Erlotinib (E) Versus Placebo (P) for Completely Resected Stage IB-IIIA EGFR-Positive (IHC/FISH) Non-Small Cell Lung Cancer (NSCLC): RADIANT Results

2014 ◽  
Vol 90 (5) ◽  
pp. S2-S3 ◽  
Author(s):  
N.K. Altorki ◽  
M.E.R. O'brien ◽  
W.E.E. Eberhardt ◽  
F.C. Richardson ◽  
J. Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stage Ib ◽  
Resected Stage

scholarly journals P1.05-014 Efficacy of Adjuvant Chemotherapy for Completely Resected Stage IB Non-Small Cell Lung Cancer

2017 ◽  
Vol 12 (11) ◽  
pp. S1983
Author(s):  
M.K. Byun ◽  
H.J. Park ◽  
H.S. Park ◽  
H. Jeung ◽  
J.Y. Cho ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stage Ib ◽  
Resected Stage

scholarly journals P2-259: A feasibility study of adjuvant carboplatin (C) plus gemcitabine (G) in completely resected stage IB–III non–small–cell lung cancer (NSCLC)

2007 ◽  
Vol 2 (8) ◽  
pp. S675-S676
Author(s):  
Atsushi Horiike ◽  
Fumiyoshi Ohyanagi ◽  
Yoshio Okano ◽  
Yukitoshi Satoh ◽  
Sakae Okumura ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Feasibility Study ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stage Ib ◽  
Resected Stage
Sign in / Sign up

Export Citation Format

Share Document